Colinz Laboratories Reports Mixed Financial Results Amid Significant Score Revision

Colinz Laboratories, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The evaluation changes indicate a notable shift in the company's score, which has seen a revision from 9 to 0 over the past three months.
On a positive note, Colinz Labs has demonstrated improvements in certain areas. The cash and cash equivalents reached a peak of Rs 8.04 crore, marking the highest level in the last six half-yearly periods, suggesting an enhancement in short-term liquidity. Additionally, the Debtors Turnover Ratio has also shown strength, recorded at 8.48 times, the highest in the last five half-yearly periods, indicating that the company has been effective in settling its debts more swiftly.

Conversely, the financial results reveal challenges for Colinz Labs. The operating profit (PBDIT) has fallen to Rs 0.06 crore, the lowest in the last five quarters, reflecting a negative trend in near-term operating profit. Similarly, the profit before tax (PBT) has also reached a low of Rs 0.02 crore, alongside a decline in earnings per share (EPS) to Rs 0.20, indicating a reduction in profitability for shareholders.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.